Stock MARI MARINOMED BIOTECH AG
Add to a list
To use this feature you must be a member
Log inSign up

News Marinomed Biotech AG

Equities

MARI

ATMARINOMED6

Market Closed - Wiener Boerse
Other stock markets
 11:35:17 2024-05-02 EDT 		5-day change 1st Jan Change
16.7 EUR -1.76% Intraday chart for Marinomed Biotech AG -12.11% -42.81%
04-16 Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024
04-16 Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios
EQ
AFR: Marinomed Biotech AG: Release of a Financial report
EQ
Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024
Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets
EQ
AFR: Marinomed Biotech AG: Release of a Financial report
EQ
Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution
EQ
Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico
EQ
Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months
EQ
Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe
EQ
Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations
EQ
Marinomed Biotech AG announces preliminary revenue for 2023
EQ
Marinomed Biotech AG with important progress for Carragelose in 2024
EQ
Marinomed Biotech Considers Partnerships, Potential Transfer of Carragelose Portfolio
MT
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
EQ
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
EQ
Marinomed Biotech Signs Deal With DKSH to Commercialize Carragelose in Four Countries
MT
Marinomed Biotech AG with new Carragelose distribution and manufacturing partners and EU patent
EQ
Transcript : Marinomed Biotech AG, Nine Months 2023 Earnings Call, Nov 21, 2023
Marinomed Biotech AG: Stable revenues in the first three quarters of 2023 and further progress in business development
EQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MARI Stock
  4. News Marinomed Biotech AG